AREAS OF SPECIALTY:

• mTOR

• rapamycin

• clinical trials targeting aging biology

Joan Mannick, MD

Joan Mannick is the Chief Executive Officer and Co-Founder of Tornado Therapeutics which is developing next generation mTOR inhibitors to treat aging-related diseases. Prior to joining Tornado, Joan Mannick was Head of Research and Development at Life Biosciences, a biotechnology company advancing treatments for age-related diseases by targeting aging biology. Prior to joining Life Biosciences, Dr. Mannick was Co-Founder and Chief Medical Officer of resTORbio which was a spinout of a clinical program targeting aging biology that she led as an Executive Director at the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research. Prior to Novartis, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas and was faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology.

Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program.